Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Cantor Fitzgerald provides update on Biotechnology stocks
-
Axsome Therapeutics (AXSM) PT Raised to $124 at Cantor Fitzgerald
-
Axsome Therapeutics (AXSM) PT Raised to $161 at Cantor Fitzgerald, Following Clinical Trial Update
-
Axsome Therapeutics (AXSM) PT Raised to $131 at Cantor Fitzgerald
-
Axsome Therapeutics (AXSM) PT Raised to $125 at Cantor Fitzgerald
-
Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Axsome Therapeutics (AXSM) Prices 2M Share Offering at $87
-
Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock
-
Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock
-
Axsome Therapeutics (AXSM) PT Raised to $104 at Cantor Fitzgerald
-
Axsome Therapeutics (AXSM) PT Raised to $55 at Cantor Fitzgerald
-
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
-
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
-
Cantor Fitzgerald Starts Axsome Therapeutics (AXSM) at Overweight
-
Axsome Therapeutics to Present at Upcoming Investor Conferences
-
Axsome Therapeutics to Present at Upcoming Investor Conferences
-
Axsome Therapeutics to Present at Upcoming Investor Conferences
-
Axsome Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
-
Cantor Fitzgerald Starts Axsome Therapeutics (AXSM) at Buy
-
Axsome Therapeutics Announces Closing of Initial Public Offering
-
Axsome Therapeutics (AXSM) IPO Opens, Trades Flat
-
Axsome Therapeutics' (AXSM) IPO Prices at $9/Share
-
Axsome Therapeutics Announces Pricing of Initial Public Offering
-
Axsome Therapeutics Announces Pricing of Initial Public Offering

